Poster: Predicting toxicity with Cell Painting & Dynamic Modeling

Format:

Predicting toxicity with Cell Painting & Dynamic Modeling

About the poster

Toxicity remains one of the major challenges in the drug discovery process, with an estimated 30% of drug candidates failing during development due to toxic effects. This highlights the ongoing need to improve current toxicity assessment methods in order to detect harmful effects as early and accurately as possible.

Despite recent technological advances, the cell based assays currently used for testing compound toxicity have significant sensitivity limitations. Typically, the concentrations at which  a toxicity effect is detected in in vitro assays greatly exceed the concentrations required to elicit toxicity in a real organism. This makes the resulting calculations for IC50 or PoD (Point of Departure) highly unreliable in in vivo studies, calling for the development of new methods capable of capturing the toxicity at lower concentrations.

To address these challenges, we’ve adapted an eXplainable Convolutional neural network for Multivariate Time Series classification (XCM) by treating concentrations as time points to analyze Cell Painting assay data. We selected this method to address the nature of increasing doses, which can mimic temporal progression. Additionally, using
a CNN-based approach enables analysis of the importance of both features and concentrations through the Grad-CAM method

This poster was originally presented during the SLAS Europe 2025 Conference.

Expert Contribution

Reviewed by: Dr. Nasim Jamali, PhD
Role: Director of Morphological Profiling, AI‑Driven Drug Discovery
Expertise: Morphological profiling, microscopy imaging, bioimage analysis, AI-driven phenotypic data interpretation, product strategy in biotech

You might be also interested in:

Biomedical knowledge graph connecting drug discovery data, disease biology, targets and indications to support target prioritization and indication expansion
Knowledge Graphs in Drug Discovery: Bringing Context to Internal Data Assets
Molecular structure representing AI-supported antibody design for blood-brain barrier research
How BBB-Penetrating Antibodies Cross the Blood-Brain Barrier
Life sciences conference takeaways 2026 - AACR, PEGS Boston, SLAS Europe, and Bio-IT World summary on AI in drug discovery
What 4 Life Sciences Conferences Revealed About AI in Drug Discovery
Life sciences professional using a tablet in front of digital data infrastructure screens
Scaling AI in Life Sciences: Why Data Infrastructure Determines Success

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!